NCT02514382View on ClinicalTrials.gov

Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 21, 2015

Primary Completion Date

April 19, 2022

Study Completion Date

April 19, 2022

Conditions
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
DRUG

Bortezomib

Given SC or IV

DRUG

Dexamethasone

Given PO, IV, or IM

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

BIOLOGICAL

Wild-type Reovirus

Given IV

Trial Locations (1)

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Oncolytics Biotech
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Oncolytics Biotech

INDUSTRY

lead

University of Southern California

OTHER

NCT02514382 - Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter